Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report
Authors:
- Albina TummoloATAlbina Tummolo
- Livio MelpignanoLMLivio Melpignano
- Antonella CarellaACAntonella Carella
- Anna Maria Di MauroAMAnna Maria Di Mauro
- Elvira PiccinnoEPElvira Piccinno
- Marcella VendemialeMVMarcella Vendemiale
- Federica OrtolaniFOFederica Ortolani
- Stefania FedeleSFStefania Fedele
- Maristella MasciopintoMMMaristella Masciopinto
- Francesco PapadiaFPFrancesco Papadia
Open Access
- 22 April 2018
- journal article
- case report
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 1-4
Abstract
Propionic acidemia is a rare autosomal recessive inherited metabolic disorder that can inhibit the synthesis of N-acetylglutamate, the obligatory activator in urea synthesis, leading to hyperammonemia. N-carbamylglutamate ameliorates hyperammonemia in decompensated propionic acidemia. The effects of long-term continuous N-acetylglutamate administration in such patients are unknown. We report our clinical experience with continuous administration of N-acetylglutamate for 6 years in a patient with propionic acidemia frequently presenting with hyperammonemia. A male Caucasian patient with frequently decompensated propionic acidemia and hyperammonemia was admitted 78 times for acute attacks during the first 9 years of his life. Continuous daily treatment with oral N-carbamylglutamate 100 mg/kg (50 mg/kg after 6 months) was initiated. During 6 years of treatment, he had a significant decrease in his mean plasma ammonia levels (75.7 μmol/L vs. 140.3 μmol/L before N-carbamylglutamate therapy, p < 0.005 [normal range 50–80 μmol/L]) and fewer acute episodes (two in 6 years). Our results suggest a benefit of N-acetylglutamate administration outside the emergency setting. If this observation is confirmed, future studies should aim to optimize the dosage and explore effects of the dosage requirements on other drugs and on protein tolerance.Keywords
This publication has 16 references indexed in Scilit:
- Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduriaMolecular Genetics and Metabolism Reports, 2016
- Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational studyOrphanet Journal of Rare Diseases, 2016
- Inhibition of N-acetylglutamate synthase by various monocarboxylic and dicarboxylic short-chain coenzyme A esters and the production of alternative glutamate estersBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemiaOrphanet Journal of Rare Diseases, 2014
- Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemiaMolecular Genetics and Metabolism, 2013
- Successful Early Management of a Female Patient With a Metabolic Stroke Due to Ornithine Transcarbamylase DeficiencyPediatric Emergency Care, 2013
- Branched-chain Organic Acidurias/Acidaemias2012
- N-Carbamylglutamate in Emergency Management of Hyperammonemia in Neonatal Acute Onset Propionic and Methylmalonic AciduriaNeonatology, 2009
- Propionic acidemia: identification of twenty-four novel mutations in Europe and North AmericaMolecular Genetics and Metabolism, 2003
- Inhibition by propionyl-coenzyme A of N-acetylglutamate synthetase in rat liver mitochondria. A possible explanation for hyperammonemia in propionic and methylmalonic acidemia.Journal of Clinical Investigation, 1979